As the risk for breast and lung carcinoma is increased in patients with SSc [35,36,37,38], we could hypothesize that anti-AKT antibodies might be relevant to define a subgroup of SSc patients with increased risk for cancer. Here, AKT1 is linked to lung carcinoma.